The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Company is investing more than €100 million in the expansion of the Halle site
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
It is a two dose vaccine to be administered intramuscularly at 28 days apart
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
